Peptide-Nucleic Acids TRIZ Cases

Cyclic beta-hairpin CPPs use a D-Pro-L-Pro motif to improve endosomal escape and cytosolic delivery of larger peptide cargos.

Small peptide constructs use a Gly-Ser linker and albumin-binding core to extend therapeutic half-life while limiting immunogenicity.

A protein carrier with engineered attachment points enables flexible ARM conjugation while preserving molecule quality and immune complex formation.

Specific ferritin-binding proteins enable precise affinity purification with minimal impurities, supporting medical use and ferritin analysis.

Conjugated MGS and MTS peptides cross the BBB and target specific CNS cells, improving uptake while limiting off-target delivery.

Mild SPPS, nanofiltration, and radical desulfurization raise tirzepatide purity while reducing purification steps, metal use, and waste.

Short peptides inhibit Hsp27 phosphorylation and hnRNP A1 redistribution to suppress EV-A71 replication and propagation.

Engineered cystine knot peptides use disulfide-stabilized scaffolds to bind and inhibit VEGF-A while resisting heat and proteolytic degradation.

A rigid EAAAK linker boosts lipopeptide stability and membrane fusion inhibition across multiple coronavirus strains and mutants.

Threshold-responsive coiled-coil peptides detect cellular forces and convert conformational opening into measurable or biochemical signals in vivo.

Selective GLP-1 receptor antagonist peptides inhibit insulin secretion to treat congenital hyperinsulinism and post-bariatric hypoglycemia.

Buffer and tonicity agents keep dual GLP-1/GLP-2 injections stable, isotonic, and less irritating at the injection site.

A sequence-specific polypeptide targets ABCA1 to reduce liver and aortic lipid buildup, offering an alternative to statins for NAFLD and atherosclerosis.

A dual-binding protein targets MCL-1 and BCL-xL together to trigger cancer-cell apoptosis while limiting normal-cell side effects.

Stable triligand peptide capture agents replace fragile antibodies to detect and inhibit Akt with reliable performance across pH, temperature, and storage.

Fusion proteins with TNFα-binding and Ig Fc domains block TNFR1/TNFR2 signaling, improving immune suppression with longer protein stability.

R-configured Pam2Cys or Pam3Cys lipopeptides with IEKKIE-X0 coiled coils raise antibody avidity in synthetic virus-like particles.

Charged mutations in triple-helical polypeptides remove Fc-domain binding, enabling more selective protein capture and purification.

Synthetic CXCR3-binding peptides target adverse remodeling, fibrosis, and inflammation after myocardial injury instead of only managing symptoms.

Selective BLMP peptides bind metastatic cancer cell receptors to improve early detection and targeted therapeutic delivery.

Targeting VEGFR-1 with inhibitors promotes myelination and protects neurons in demyelinating diseases where current therapies remain inadequate.

An artificial sequence peptide offers a pharmacological approach for traumatic brain injury, improving motor and memory function across stages.

A modified GIP/GLP-1 peptide activates both receptors and resists DPP-IV inactivation for sustained glycemic and weight control.

Solid-phase-synthesized peptide scaffolds self-assemble into hapten carriers, reducing reliance on time-consuming recombinant hosts for subunit vaccines.